Identification of Women of Polycystic Ovary Syndrome (PCOS) At Risk for Generation of Metabolic Disease in Normal Weight PCOS: Is There a Role of Flutamide?- A Short Communication

Kulvinder Kochar Kaur^1*, Gautam Nand Allahbadia, K.² & Mandeep Singh³

¹Department of Obstt & Gynae, Specialist Reproductive Endocrinology & Infertility Specialist, Scientific Director cum Owner Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar-144001, Punjab, India
²Department of Obstt & Gynae, Scientific Director, Ex-Rotunda-A Centre for Human Reproduction, 672, Kalpak Garden, Perry Cross Road, Near Otter’s Club,Bandra(W)-400040, Mumbai, India
³Department of Neurology, Consultant Neurologist, Swami Satyanand Hospital, Near Nawi Kachehri, Baradri, Ladowali road, Jalandhar, Punjab, India

Dr. Kulvinder Kochar Kaur, Obstt & Gynae, Specialist Reproductive Endocrinology & Infertility Specialist, Scientific Director cum Owner Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar-144001, Punjab, India.

Keywords: Polycystic Ovary Syndrome; Flutamide

Abstract

Polycystic ovary syndrome (PCOS) possesses the properties of ovarian hyperandrogenism (HA) from changes in the hypothalamo-pituitary-ovarian(H-P-O)axis in association with insulin resistance(IR) [1]. As per the definitions, in1990 PCOS definition in women accepted as per National Institute of Health (NIH) criteria [1], i.e. clinical and/or biochemical androgen excess plus oligo anovulation with exclusion of specific etiologies like hyperprolactinemia, and 21 hydroxylase deficiency, escalated androgen in general is correlated with predisposition to abdominal fat accrual, that in turn is exacerbated by obesity along with escalated incidence of generation of type2 Diabetesmellitus (T2DM), dyslipidemia as well as Metabolic Syndrome(MetS) [1-4].

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).